Venous Thrombosis Assay in a Mouse Model of Cancer
January 5th, 2024
This article aims to present an optimized method for assessing venous thrombosis in a mouse cancer model, using vascular clips to achieve venous ligation. Optimization minimizes variability in thrombosis-related measurements and enhances relevance to human cancer-associated venous thrombosis.
This research aims to enhance the rodents model for venous thrombosis, focusing on cancer-associated thrombosis. It introduces a refined surgical technique using vascular clips in a syngenic colon cancer xenograft mouse model to improve consistency and reproducibility. Our vast cancer associated thrombosis mechanistic understanding, and drug discovery.
Although the flow reduction model was introduced in the IVC stenotic models in 2012, no significant progress has been made in cancer associated thrombosis models in the last 10 years. This was the rationale for this endeavor. In the field of cancer associated thrombosis research, current technologies include advanced imaging techniques like scanning electron microscopic images, molecular biology tools such as immunofluorescence staining, precision surgical instrument, data analysis software and data interpretation, And animal welfare.
The current experimental challenges include variability in claw waste, a high mortality rate, and a prolonged learning curve in rodent models of venous thrombosis. Additionally, the venous flow direction and clot formation mechanisms differ from clinical cases. Our research protocol bridges gaps in rodent models of cancer associated thrombosis.
It introduces a novel surgical technique using vascular clips in xenograft models, yielding more consistent and reproducible thrombosis outcomes. This enhances our understanding of cancer related thrombosis and drug discovery in translational research. To begin, use a pair of fine scissors to make an incision on the abdominal skin of an anesthetized mouse, starting from the zyphoidal eminence to the bladder.
With a pair of atraumatic forceps, pinch the peritoneum halfway along the skin incision, ensuring an adequate gap between the incision and the overlying intestines. Next, open the peritoneum longitudinally along the avascular linea alba. Then use wet cotton tips to pull out the intestines carefully.
Then drop 200 to 300 microliters of normal saline over the intestines, and explore the route of the ureters inferior vena cava or IVC, aorta and renal veins. Cauterize the bilateral branches distal to the confluence of the left renal vein and infrarenal inferior vena cava. Check the ureters and vasculature for any oozing.
To prevent potential complications of spinal ischemia and claudication, leave the lumbar branches intact. Check for the side branches, including the bilateral uterine horn and hypogastric vessels. Next, use a closed tip atraumatic forceps to gently pass a six zero polypropylene suture through the avascular plane, two to three times.
Apply gentle pressure with a cotton tip tapinate to control any oozing. Finally, pass a five zero polypropylene suture through the plane with gentle coddled to cranial movements to widen it. Place the vascular clamps over the suture to guarantee adequate space.
Clot weights of the xenograft experimental group displayed a 1.5 fold increase relative to the control mice. Immunofluorescence assays showed that the IVC from the control group had intact CD 31 and fibrin partially occupying the vessel lumen. The CD 31 expression was not intact in the experimental group with the wall showing fibrin staining.
The control group had significantly lower fibrin expression compared to the experimental group. Ultrasonic graphic analysis of the mice showed the ligated infrarenal vena cava of a control group mouse had a partial clot. The experimental group, however, had a large clot, nearly occluding the infrarenal vena cava.
Overview
This research enhances the rodent model for venous thrombosis, particularly in cancer-associated thrombosis. It introduces a refined surgical technique using vascular clips in a syngenic colon cancer xenograft mouse model to improve consistency and reproducibility.
Key Study Components
Area of Science
- Neuroscience
- Oncology
- Vascular Biology
Background
- Current technologies in cancer-associated thrombosis research include advanced imaging techniques and molecular biology tools.
- Previous models, such as IVC stenotic models, have not seen significant advancements in the last decade.
- Understanding cancer-associated thrombosis is crucial for drug discovery and therapeutic interventions.
- Animal welfare considerations are integral to the research methodology.
Purpose of Study
- To optimize the assessment of venous thrombosis in a mouse cancer model.
- To minimize variability in thrombosis-related measurements.
- To enhance the relevance of findings to human cancer-associated venous thrombosis.
Methods Used
- Refined surgical technique using vascular clips for venous ligation.
- Syngenic colon cancer xenograft mouse model.
- Advanced imaging techniques for assessment.
- Data analysis software for interpretation of results.
Main Results
- Improved consistency and reproducibility in thrombosis measurements.
- Enhanced understanding of cancer-associated thrombosis mechanisms.
- Potential implications for drug discovery in cancer treatment.
- Validated the use of vascular clips in surgical procedures.
Conclusions
- The optimized method provides a reliable model for studying venous thrombosis.
- Findings may lead to better therapeutic strategies for cancer-associated thrombosis.
- Future research can build on this methodology to further explore thrombosis in cancer.
Frequently Asked Questions
Executive Industry Relevance
Reliable preclinical models of cancer-associated venous thrombosis are essential for translational drug discovery and mechanistic de-risking in oncology portfolios. This refined mouse model using vascular clips addresses variability and reproducibility challenges, enabling more predictive assessment of thrombosis mechanisms and therapeutic interventions. Enhanced model consistency supports confident target validation and risk-adjusted advancement decisions in early discovery and translational research.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables mechanistic interrogation of cancer-associated thrombosis pathways in vivo.
- Reduces biological ambiguity by providing reproducible thrombosis outcomes for hypothesis testing.
- Supports functional target validation by correlating clot formation with molecular markers.
- Facilitates portfolio triage by improving predictive confidence in thrombosis-related targets.
Screening & Assay Development
- Prepares validated animal models for downstream efficacy and mechanistic screening of antithrombotic agents.
- Improves assay standardization and reproducibility through consistent clot mass and surface area measurements.
- Enables quantitative outputs for comparative evaluation of candidate compounds.
- Supports scalable and reusable model systems for iterative screening workflows.
Translational & Preclinical Research
- Aligns preclinical thrombosis models with disease-relevant mechanisms observed in cancer patients.
- Provides continuity from discovery through preclinical validation by integrating imaging and molecular readouts.
- Enables risk-adjusted advancement of antithrombotic strategies based on robust in vivo data.
- Supports translational biomarker development through immunofluorescence and imaging correlation.
Pipeline & Workflow Integration
This refined thrombosis model fits within the early discovery to preclinical continuum, supporting both mechanistic studies and translational drug evaluation in cancer-associated thrombosis.
- Discovery Biology: Facilitates hypothesis testing and pathway clarification for thrombosis mechanisms in cancer models.
- Screening: Provides reproducible, quantitative clot measurements for assay readiness and compound evaluation.
- Analytics: Integrates imaging and immunofluorescence outputs for robust statistical comparison of experimental groups.
- Translational Research: Bridges discovery and preclinical validation by modeling clinically relevant thrombosis phenotypes.
- Enterprise Reuse: Establishes a standardized, reusable platform for ongoing thrombosis research and drug screening.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in thrombosis research.
- Operational Value: Enhances standardization, reproducibility, and scalability of preclinical thrombosis models.
- Strategic Value: Improves go/no-go decision quality and capital efficiency by reducing late-stage biological risk.
- Portfolio Impact: Enables risk-adjusted prioritization and advancement of thrombosis-targeted therapies.
Implementation Considerations
- Requires surgical expertise in vascular clip placement and animal model handling.
- Needs access to advanced imaging and immunofluorescence analysis infrastructure.
- Demands cross-team standardization of surgical and analytical protocols for reproducibility.
- May require adaptation for different cancer types or thrombosis models as supported by the protocol.
- Limitations include model-specific mortality rates and learning curve for surgical refinements.
